74 related articles for article (PubMed ID: 23200895)
21. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effects of ICI 182,780 on the cytotoxicity of cisplatin in cervical carcinoma cell lines.
García-López P; Rodríguez-Dorantes M; Pérez-Cárdenas E; Cerbón M; Mohar-Betancourt A
Cancer Chemother Pharmacol; 2004 Jun; 53(6):533-40. PubMed ID: 15138713
[TBL] [Abstract][Full Text] [Related]
23. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
24. [Effect of hepatocyte growth factor on invasion of ovarian cancer cell line SKOV3 and its signal transduction pathway].
Wang HL; Zhang SL; Lu YM; Jiang JY; Zhu XY
Ai Zheng; 2006 May; 25(5):570-5. PubMed ID: 16687076
[TBL] [Abstract][Full Text] [Related]
25. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
26. Hepatocyte growth factor promotes in vitro scattering and morphogenesis of human cervical carcinoma cells.
Wong AS; Leung PC; Auersperg N
Gynecol Oncol; 2000 Aug; 78(2):158-65. PubMed ID: 10926796
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells.
Shen YH; Chen BR; Cherng SH; Chueh PJ; Tan X; Lin YW; Lin JC; Chuang SM
Toxicol Lett; 2011 Sep; 205(3):341-50. PubMed ID: 21742020
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
29. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
31. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
32. Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells.
Okada T; Murata K; Hirose R; Matsuda C; Komatsu T; Ikekita M; Nakawatari M; Nakayama F; Wakatsuki M; Ohno T; Kato S; Imai T; Imamura T
Sci Rep; 2013 Oct; 3():2899. PubMed ID: 24113164
[TBL] [Abstract][Full Text] [Related]
33. AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer.
Bi L; Ma F; Tian R; Zhou Y; Lan W; Song Q; Cheng X
Gene; 2018 Feb; 644():148-154. PubMed ID: 29126926
[TBL] [Abstract][Full Text] [Related]
34. Metformin and caffeic acid regulate metabolic reprogramming in human cervical carcinoma SiHa/HTB-35 cells and augment anticancer activity of Cisplatin via cell cycle regulation.
Tyszka-Czochara M; Bukowska-Strakova K; Majka M
Food Chem Toxicol; 2017 Aug; 106(Pt A):260-272. PubMed ID: 28576465
[TBL] [Abstract][Full Text] [Related]
35. The effect of Chaihu-shugan-san on cytotoxicity induction and PDGF gene expression in cervical cancer cell line HeLa in the presence of paclitaxel +cisplatin.
Jianfang X; Ling Z; Yanan J; Yanliang G
Cell Mol Biol (Noisy-le-grand); 2021 Nov; 67(3):143-147. PubMed ID: 34933719
[TBL] [Abstract][Full Text] [Related]
36. Involvement of Src signaling in the synergistic effect between cisplatin and digoxin on cancer cell viability.
Pereira DG; Salgado MAR; Rocha SC; Santos HL; Villar JAFP; Contreras RG; Fontes CFL; Barbosa LA; Cortes VF
J Cell Biochem; 2018 Apr; 119(4):3352-3362. PubMed ID: 29130514
[TBL] [Abstract][Full Text] [Related]
37. RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance.
Mokady D; Meiri D
Drug Resist Updat; 2015 Mar; 19():22-32. PubMed ID: 25660168
[TBL] [Abstract][Full Text] [Related]
38. Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance.
Hougardy BM; Maduro JH; van der Zee AG; Willemse PH; de Jong S; de Vries EG
Lancet Oncol; 2005 Aug; 6(8):589-98. PubMed ID: 16054570
[TBL] [Abstract][Full Text] [Related]
39. Cellular landscaping of cisplatin resistance in cervical cancer.
Bhattacharjee R; Dey T; Kumar L; Kar S; Sarkar R; Ghorai M; Malik S; Jha NK; Vellingiri B; Kesari KK; Pérez de la Lastra JM; Dey A
Biomed Pharmacother; 2022 Sep; 153():113345. PubMed ID: 35810692
[TBL] [Abstract][Full Text] [Related]
40. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin.
Belenkov AI; Shenouda G; Rizhevskaya E; Cournoyer D; Belzile JP; Souhami L; Devic S; Chow TY
Mol Cancer Ther; 2004 Dec; 3(12):1525-32. PubMed ID: 15634645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
